{"id":"NCT02533375","sponsor":"AbbVie","briefTitle":"Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","officialTitle":"A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-28","primaryCompletion":"2016-09-15","completion":"2017-07-20","firstPosted":"2015-08-26","resultsPosted":"2019-01-14","lastUpdate":"2019-01-14"},"enrollment":10,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Pustular Psoriasis (GPP)","Adalimumab","Japanese"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira","ABT-D2E7"]}],"arms":[{"label":"Participants receiving adalimumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.","primaryOutcome":{"measure":"Proportion of Participants Achieving Clinical Response at Week 16","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Participants Receiving Adalimumab","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":10},"commonTop":["Nasopharyngitis","Pruritus","Hypoalbuminaemia","Eosinophilia","Cardiac failure"]}}